Bioverativ appoints new head of research and development

Pharmaceutical Company Restructures

Bioverativ has announced the appointment of Dr Tim Harris as its new executive vice-president of research and development.

Dr Harris can boast more than three decades of scientific and leadership expertise, serving most recently as a venture partner at SV Life Sciences, where he helped to identify and analyse investment opportunities for its two newest funds.

“Bioverativ has appointed Tim Harris as its new executive vice-president for research and development.“

From 2011 to 2016, he was senior vice-president of precision medicine and translational medicine and biochemistry at Biogen, Bioverativ's former parent company, from which it separated earlier this year.

In his new role, Dr Harris will be responsible for leading Bioverativ's scientific direction, advancing pipeline programmes and optimising research and development operations.

John Cox, chief executive officer of Bioverativ, said: "He has a proven track record of leading research and development teams that push scientific boundaries, which will be instrumental in helping us rapidly advance our pipeline."

Dr Harris expressed excitement about the prospect of working with the same team that developed Eloctate and Alprolix, the first major advancements in haemophilia treatment in nearly 20 years.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news